RESEARCH ARTICLE DOI: 10.53555/jptcp.v30i19.4798

APPROACH TO ASTHMA AND MODALITIES OF MANAGEMENT

Nabeel Jaber Alharbi^{1*}, Sultan Fahad Almaghrabi², Haytham Nabil Alhazmi³, Atif Mohammed Hakami², Mohammad Zain Raddadi⁵, Samirah Abdullah M Alameer⁶, Hanan Mohammed Muadah Masrahi⁷

Chest Diseases Hospital - Jazan - Abu Arish - Saudi Arabia
Ajyad Emergency Hospital - Makkah - Saudi Arabia
King Fahad Hospital - Medinah - Saudi Arabia
Al-Fath Primary Health Care - Medinah - Saudi Arabia
Sabya General Hospital - Jazan - Saudi Arabia
King Faisal Medical Complex - Taif - Saudi Arabia

*Corresponding Author: Nabeel Jaber Alharbi *Chest Diseases Hospital - Jazan - Abu Arish - Saudi Arabia

Abstract:

Background: Asthma is a chronic respiratory condition characterized by inflammation in the airways, leading to recurring episodes of wheezing, breathlessness, chest tightness, and coughing. These symptoms often occur due to the airways' heightened sensitivity to various triggers, resulting in temporary narrowing and obstruction. Asthma can affect individuals of all ages, and its severity can vary from mild to severe.

Aim: The literature review aims to overview the latest update on the approach to asthma and various management modalities.

Methods: The present study is a comprehensive research of PUBMED from 2000 to 2023.

Conclusion: Despite being prevalent in both children and adults, adults tend to have higher morbidity and mortality rates. Recent research suggests a possible link between sex hormones and asthma development. The disease's prevalence has increased globally, likely due to environmental factors. Asthma's pathophysiology involves complex interactions between immune cells and molecules, leading to airway inflammation, hyperresponsiveness, obstruction, and remodeling. Symptoms include wheezing, coughing, chest tightness, and breathlessness, which vary in severity and frequency. Asthma can manifest in different phenotypes, classified based on inflammatory cell profiles and clinical features. Diagnosis relies on clinical evaluation, lung function tests, and objective measurements. Treatment aims to control symptoms and prevent exacerbations using inhaled corticosteroids, long-acting β2-agonists, and combination inhalers.

Keywords: Asthma, chronic respiratory disease, diagnosis, treatment.

Introduction:

Asthma is a chronic lung disease characterized by inflammation in the bronchioles, narrowing of the airways, and airflow obstruction, which can present in children and adults [1]. Nevertheless, Adults with asthma have a greater morbidity and mortality rate than children despite an increase in incidence and frequency. A recent review represented that females are more likely than males to have adult asthma, though this trend may be reversible. Around puberty, there is a difference in prevalence between the sexes, which suggests that sex hormones may be involved in the etiology of asthma [2]. Asthma is one of the most prevalent chronic illnesses worldwide, and the previous few decades have seen an upsurge in the prevalence of asthma globally, according to epidemiologic data. Moreover, there are over 310 million asthmatic patients in the world. The prevalence of bronchial asthma rises annually as environmental factors and air quality worsen [3]. The pathophysiology of asthma involves a complex interplay of various factors. Airway inflammation plays a major role in the development of asthma, with different cells and molecules contributing to the inflammatory process. Multiple molecular pathways are involved in asthma, including immunoglobulin E, cytokines, nitric oxide, and oxidative stress. Airway hyperresponsiveness, variable airway obstruction, hypersecretion, and airway remodeling are physiological manifestations of asthma resulting from the activation of the immune system and its interaction with epithelial cells [3]. Asthma symptoms include nonspecific manifestations such as wheezing, coughing, chest tightness, and shortness of breath. These symptoms can vary between individuals and over time, spontaneously, in response to triggers, or as a result of treatment. The frequency and severity of symptoms can differ among individuals, and they may experience inadequate asthma control for various reasons, including severe disease, ineffective treatment, nonadherence to treatment, and the effects of comorbidities [4].




Figure (1): Asthma phenotypes based on inflammatory cell profile

Asthma has been identified as having multiple phenotypes based on inflammatory cell profiles in sputum. These phenotypes include eosinophilic, neutrophilic, paucigranulocytic, and mixed-granulocytic asthma. In addition to these inflammatory phenotypes, there is anatomical heterogeneity in asthma, with immunopathological alterations extending beyond the central airways to involve the distal airways, alveolar parenchyma, pulmonary vessels, and extrapulmonary tissues [5,6]. The distribution of inflammation in asthma can have implications for clinical presentation and response to treatment, with small airway disease and distal lung inflammation being common features. In 2023, the Global Initiative for Asthma (GINA) has released annually revised guidelines for asthma management and prevention in children and adults. The eosinophilic phenotype is characterized by the expansion of eosinophilic infiltration in the airways, making asthmatic patients susceptible to asthma triggered by exposure to allergens. The neutrophilic phenotype is mainly due to increased neutrophilic infiltration of the airways, which makes the patients more susceptible to severe, aggressive, and uncontrolled asthma. The paucigranulocytic phenotype involves no elevation of either cell count, and lastly, the mixed-granulocytic phenotype involves concurrent increases in both cell

counts (figure 1) [6]. Professional associations like (the European Respiratory Society, American Thoracic Society, Global Initiative for Asthma, etc.) tend to accentuate a mix of clinical and pathophysiological factors. Another classification of asthma was identified according to the clinical phenotypes: atopic asthma, nonatopic asthma, obese asthma, late-onset asthma with severe obstructive syndrome, occupational asthma, and aspirin-sensitive asthma [7].

DIFFERENTIAL DIAGNOSIS

The differential diagnosis for asthma involves considering other diseases with similar clinical manifestations. A detailed history and supportive pulmonary function tests are necessary to diagnose asthma properly, as the differential diagnosis is broad (Figure 2).

Vocal cord Congestive Obstructive sleep rhinopathy dysfunction apnea syndrome Hyperventilation Chronic syndrome / obstructive **Bronchiectasis** Cystic fibrosis pulmonary pneumonia dysfunctional breathing disease Chronic Cardiovascular Congestive heart **Pulmonary** thromboembolic Left ventricular pulmonary failure hypertension dysfunction disease Gastroesophageal reflux disease Central nervous Habitual cough

Figure (2): Differential diagnosis of Asthma

DIAGNOSIS OF ASTHMA:

Asthma diagnosis is an area of ongoing research, and there have been recent updates in this field. The lack of a gold standard test for asthma diagnosis has contributed to both overdiagnosis and underdiagnosis of the condition. As a result, current international guidelines emphasize the need for a standardized approach to diagnosis, including objective measurements before treatment. Asthma diagnosis involves clinical assessment, diagnostic testing, and objective lung function measurements. Symptoms of asthma include cough, dyspnea, and wheezing, although they can vary greatly between patients and over time [8]. Objective tests such as spirometry with bronchodilator reversibility testing are the mainstays for diagnosing asthma in children and adults (Figure 3) [9]. These tests demonstrate airway obstruction and variability in the degree of obstruction, characteristic of asthma. Additional tests, such as bronchial challenge testing and measurement of eosinophilic inflammation or atopy by sputum eosinophil counts, checking IgE levels can provide supportive evidence for the diagnosis of asthma.




Figure (3): Algorithm for The Diagnosis of Asthma [10]

Laboratory test for asthma:

It is important to follow up on kidney function for asthmatic patients using a high dose or repeats of salbutamol, urea, and electrolytes as it may temporarily shift potassium into the intracellular space, which might result in temporary iatrogenic hypokalemia. Also, arterial blood gas may detect hypoxemia and respiratory acidosis [11].

Imaging:

Chest X-ray (CXR) is commonly used in the management of acute asthma exacerbation despite guidelines advising against routine use. Other radiological imaging modalities, such as computed tomography (CT) and magnetic resonance imaging (MRI), can play a role in identifying distinct asthma phenotypes and assessing response to therapy.






Figure (5): A CT scan for an asthmatic patient shows bronchiectasis in both upper lobes consistent with allergic bronchopulmonary aspergillosis [11].



TREATMENT:

Asthma treatment aims to minimize the symptoms and maintain daily activity without deterioration. The new gold standard for asthma treatment uses gold nanoparticles for drug delivery. Medical practitioners must approach the patients with a guideline-based plan to avoid specific environmental triggers, including pollutants, respiratory viruses, allergens, non-allergen substances, or irritants encountered in occupational, household, or environmental settings.

Current pharmacological treatments for asthma include inhaled corticosteroids (ICS), long-acting β2-agonists (LABA), and combination inhalers containing both ICS and LABA. These treatments effectively control the underlying airway inflammation and reduce symptoms and exacerbations [12]. Additionally, long-acting antimuscarinic agents (LAMA) have been added to ICS/LABA treatment to improve asthma control by targeting small airway disease [13]. However, there are still unmet needs in treating severe asthma, motivating research to identify novel targets and develop improved therapies [14]. Leukotriene antagonists, a new class of anti-asthma therapy, have been developed but are less efficient than currently available medications [15]. The success of fixed-dose combination inhalers has created "bifunctional" drugs with two distinct pharmacological actions. The new gold

standard for asthma treatment uses gold nanoparticles for drug delivery. Gold nanoparticles have many advantages, such as high dispersion power and reduced drug side effects when used in conjunction with the drug [16]. Additionally, probiotics have shown potential beneficial effects on asthma prevention and treatment, making them an attractive therapeutic option [17]. However, the use of gold compounds as a steroid-sparing agent in chronic severe asthma has shown only small treatment effects and significant side effects, limiting their recommendation [18]. Overall, while current pharmacological treatments are effective in managing asthma, there is a need for further research and development to address the limitations and unmet needs in asthma treatment.

How do nurses collaborate with other healthcare professionals to effectively manage asthma?

Nurses collaborate with other healthcare professionals to effectively manage asthma through a multidisciplinary and collaborative approach. They are crucial in assessing patients' risk of developing respiratory failure, monitoring patients, evaluating their care, and coordinating an interdisciplinary approach. Nursing interventions are relatively effective in improving the quality of life and reducing asthma-related emergencies, acute attacks, and hospitalizations among childhood asthma patients [19]. Nurses and care coordinators can partner with and empower older adults with asthma to practice disease self-management and improve their health-related outcomes through adult learner techniques, clear communication, education, and care coordination support [20]. Effective, shared decision-making and improved quality of life for people with asthma can be achieved through good communication skills and empowering patients to be involved in asthma management, which requires training for healthcare professionals [21].

Conclusion:

Asthma is a chronic lung condition marked by inflammation, airway narrowing, and airflow blockage. Despite being prevalent in both children and adults, adults tend to have higher morbidity and mortality rates. Recent research suggests a possible link between sex hormones and asthma development. The disease's prevalence has increased globally, likely due to environmental factors. Asthma's pathophysiology involves complex interactions between immune cells and molecules, leading to airway inflammation, hyperresponsiveness, obstruction, and remodeling. Symptoms include wheezing, coughing, chest tightness, and breathlessness, which vary in severity and frequency. Asthma can manifest in different phenotypes, classified based on inflammatory cell profiles and clinical features. Diagnosis relies on clinical evaluation, lung function tests, and objective measurements. Treatment aims to control symptoms and prevent exacerbations using inhaled corticosteroids, long-acting β2-agonists, and combination inhalers.

References:

- 1. Sims JM: An Overview of Asthma. Dimensions of Critical Care Nursing. 2006, 25.
- 2. Dharmage SC, Perret JL, Custovic A: Asthma epidemiology in children and adults. Frontiers in pediatrics. 2019, 7:246.
- 3. Shinde V, Wankhede P, Vyawahare N: Asthma: Cells involved in the pathophysiology of asthma. The Journal of Association of Chest Physicians. 2023, 11:10-18.
- 4. Holgate ST: 7 Asthma. Allergy Essentials (Second Edition). O'Hehir RE, Holgate ST, Khurana Hershey GK, Sheikh A (eds): Elsevier, Philadelphia; 2022. 123-169. https://doi.org/10.1016/B978-0-323-80912-2.00007-X
- 5. Feng Y, Liu X, Wang Y, Du R, Mao H: Delineating asthma according to inflammation phenotypes with a focus on paucigranulocytic asthma. Chinese Medical Journal. 2023, 136.
- 6. Matabuena M, Salgado FJ, Nieto-Fontarigo JJ, et al.: Identification of Asthma Phenotypes in the Spanish MEGA Cohort Study Using Cluster Analysis. Archivos de Bronconeumología. 2023, 59:223-231. https://doi.org/10.1016/j.arbres.2023.01.007
- 7. McCracken JL, Veeranki SP, Ameredes BT, Calhoun WJ: Diagnosis and Management of Asthma in Adults: A Review. Jama. 2017, 318:279-290. 10.1001/jama.2017.8372

- 8. Zhan J, Chen W, Cheng L, Wang Q, Han F, Cui Y: Diagnosis of Asthma Based on Routine Blood Biomarkers Using Machine Learning. Computational Intelligence and Neuroscience. 2020, 2020:1-8. 10.1155/2020/8841002
- 9. Saglani S, Menzie-Gow AN: Approaches to Asthma Diagnosis in Children and Adults. Frontiers in Pediatrics. 2019, 7. 10.3389/fped.2019.00148
- 10. Ukena D, Fishman L, Niebling WB: Bronchial asthma: diagnosis and long-term treatment in adults. Dtsch Arztebl Int. 2008, 105:385-394. 10.3238/arztebl.2008.0385
- 11. Hashmi MF, Tariq M, Cataletto ME, Hoover EL: Asthma (Nursing). 2021.
- 12. Cazzola M, Page CP, Matera MG, Rogliani P, Hanania NA: Revisiting asthma pharmacotherapy: where do we stand and where do we want to go? European Respiratory Journal. 2023, 62:2300700. 10.1183/13993003.00700-2023
- 13. Amison RT, Page CP: Novel pharmacological therapies for the treatment of bronchial asthma. Minerva Medica. 2021, 113:31-50.
- 14. Pera T, Loblundo C, Penn RB: 4.34 Pharmacological Management of Asthma and COPD. Comprehensive Pharmacology. Kenakin T (ed): Elsevier, Oxford; 2022. 762-802. https://doi.org/10.1016/B978-0-12-820472-6.00095-5
- 15. Cazzola M, Rogliani P, Naviglio S, Calzetta L, Matera MG: An update on the currently available and emerging synthetic pharmacotherapy for uncontrolled asthma. Expert Opinion on Pharmacotherapy. 2022, 23:1205-1216. 10.1080/14656566.2022.2083955
- 16. Mehrabi Nasab D, Taheri A, Athari SS: Design and Fabrication of Gold Nanoparticles for Anti-Asthma Drug Delivery. Archives of Medical Laboratory Sciences. 2020, 6:1-7 (e4). 10.22037/amls.v6.32580
- 17. Moermans C, Graff S, Laurie M, et al.: Effects of probiotics in uncontrolled asthma. Eur Respiratory Soc; 2022.
- 18. Evans DJ, Cullinan P, Geddes DM, Walters EH, Milan SJ, Jones P: Gold as an oral corticosteroid sparing agent in stable asthma. Cochrane Database of Systematic Reviews. 2000. 10.1002/14651858.CD002985
- 19. Tao S, Fan Q, Hariharan VS, Zhi H: Effectiveness of nursing interventions for management of children with bronchial asthma: A systematic review and meta-analysis. International Journal of Nursing Practice. 2023, 29:e13139. https://doi.org/10.1111/ijn.13139
- 20. Bernstein CK, Tolomeo C: How Care Coordinators and Other Nursing Professionals Can Help Optimize Care of Asthma in Older Adults. Treatment of Asthma in Older Adults: A Comprehensive, Evidence-Based Guide. Epstein TEG, Nyenhuis SM (eds): Springer International Publishing, Cham; 2019. 101-111. 10.1007/978-3-030-20554-6_9
- 21. Gruffydd-Jones K, Hansen K: Working for Better Asthma Control: How Can We Improve the Dialogue Between Patients and Healthcare Professionals? Advances in Therapy. 2020, 37:1-9. 10.1007/s12325-019-01131-0